Repurposing metformin for the prevention of cancer and cancer recurrence

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1639-1647

  Heckman Stoddard, Brandy M ^a   DeCensi, Andrea ^b,c   Sahasrabuddhe, Vikrant V ^a   Ford, Leslie G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GALLIERA HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Cancer prevention; Cancer recurrence; Chemoprevention; Metformin; Review

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL RESEARCH; DRUG MECHANISM; EFFECT SIZE; HUMAN; MALIGNANT NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG REPOSITIONING; NEOPLASM; PROCEDURES;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG REPOSITIONING; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 85026813759     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4372-6     Document Type: Review

References (61)

1. Zhou M, Xia L, Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956–1962
2. Bailey C (2017) Metformin: historical overview. Diabetologia. doi:10.1007/s00125-017-4318-z
3. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2:778–790
4. Han G, Gong H, Wang Y, Guo S, Liu K (2015) AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther 16:77–87
5. Zhao D, Long XD, Lu TF et al (2015) Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer 136:2556–2565
6. Gonzalez-Angulo AM, Meric-Bernstam F (2010) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16:1695–1700
7. Cameron AR, Morrison VL, Levin D et al (2016) Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 119:652–665
8. Saitoh R, Sugano K, Takata N et al (2004) Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm Res 21:749–755
9. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J (2007) Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 35:1333–1340
10. Chen L, Shu Y, Liang X et al (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983–9988
11. Cai H, Zhang Y, Han TK, Everett RS, Thakker DR (2016) Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. Int J Cancer 138:2281–2292
12. Wheaton WW, Weinberg SE, Hamanaka RB et al (2014) Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3:e02242
13. Birsoy K, Possemato R, Lorbeer FK et al (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508:108–112
14. Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW (2016) Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab 24:728–739
15. Bao B, Wang Z, Ali S et al (2012) Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 5:355–364
16. Ben Sahra I, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576–3586
17. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507–7511
18. DeCensi A, Puntoni M, Goodwin P et al (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3:1451–1461
19. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A (2013) Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 8:e71583
20. Noto H, Goto A, Tsujimoto T, Noda M (2012) Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7:e33411
21. Soranna D, Scotti L, Zambon A et al (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17:813–822
22. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62:922–934
23. Wu L, Zhu J, Prokop LJ, Hassan Murad M (2015) Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Sci Rep 5:10147
24. Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7:867–885
25. Zhang P, Li H, Tan X, Chen L, Wang S (2013) Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 37:207–218
26. Lega IC, Shah PS, Margel D, Beyene J, Rochon PA, Lipscombe LL (2014) The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomark Prev 23:1974–1984
27. Zhang ZJ, Li S (2014) The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 16:707–710
28. Stevens RJ, Ali R, Bankhead CR et al (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593–2603
29. Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E (2016) Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol 43:123–133
30. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
31. Jung YS, Park CH, Eun CS, Park DI, Han DS (2017) Metformin use and the risk of colorectal adenoma: a systematic review and meta-analysis. J Gastroenterol Hepatol 32:957–965
32. He XK, Su TT, Si JM, Sun LM (2016) Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis. Medicine 95:e2749
33. Nie Z, Zhu H, Gu M (2016) Reduced colorectal cancer incidence in type 2 diabetic patients treated with metformin: a meta-analysis. Pharm Biol 54:2636–2642
34. Rokkas T, Portincasa P (2016) Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis. Eur J Intern Med 33:60–66
35. Yang T, Yang Y, Liu S (2015) Association between metformin therapy and breast cancer incidence and mortality: evidence from a meta-analysis. J Breast Cancer 18:264–270
36. Perez-Lopez FR, Pasupuleti V, Gianuzzi X, Palma-Ardiles G, Hernandez-Fernandez W, Hernandez AV (2017) Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas 101:6–11
37. Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ (2016) Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget 7:66202–66211
38. Wan G, Yu X, Chen P et al (2016) Metformin therapy associated with survival benefit in lung cancer patients with diabetes. Oncotarget 7:35437–35445
39. Coyle C, Cafferty FH, Vale C, Langley RE (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27:2184–2195
40. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL (2016) Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control 27:105–113
41. Zhou PT, Li B, Liu FR et al (2017) Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget 8:25242–25250
42. Tian RH, Zhang YG, Wu Z, Liu X, Yang JW, Ji HL (2016) Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Clin Transl Oncol 18:641–649
43. Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U (2015) Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 18:110–121
44. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR (2010) Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33:1304–1308
45. Chak A, Buttar NS, Foster NR et al (2015) Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 13:665–672
46. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 8:501–505
47. Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51
48. Campagnoli C, Pasanisi P, Abba C et al (2012) Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer 12:175–182
49. Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783–794
50. Bonanni B, Puntoni M, Cazzaniga M et al (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30:2593–2600
51. Niraula S, Dowling RO, Ennis M et al (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821–830
52. Kalinsky K, Crew KD, Refice S et al (2014) Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Investig 32:150–157
53. Hosono K, Endo H, Takahashi H et al (2010) Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res 3:1077–1083
54. Higurashi T, Hosono K, Takahashi H et al (2016) Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol 17:475–483
55. Schuler KM, Rambally BS, DiFurio MJ et al (2015) Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med 4:161–173
56. Mitsuhashi A, Kiyokawa T, Sato Y, Shozu M (2014) Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer 120:2986–2995
57. Sivalingam VN, Kitson S, McVey R et al (2016) Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer 114:281–289
58. Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M (2016) Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 27:262–266
59. Curry J, Johnson J, Tassone P et al (2017) Metformin effects on head and neck squamous carcinoma microenvironment: window of opportunity trial. Laryngoscope. doi:10.1002/lary.26489
60. Joshua AM, Zannella VE, Downes MR et al (2014) A pilot /`window of opportunity/' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17:252–258
61. The Diabetes Prevention Program Research Group (1999) The diabetes prevention program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634